Figure 1 (Rituxan 01)
Rituxan Injection, Solution
Product Images NDC 50242-053
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rituxan (NDC 50242-053). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Rituxan 02)
This text represents a graph or a chart that shows the percentage of ACR 20 Responders after receiving either a placebo or a 2x1000mg dose of Rituxan at different time points (from 0 to 24 weeks).*
Figure 3 (Rituxan 03)
Principal Display Panel (100 mg Vial Carton)
This is a product information for Rituxan® (rituximab) Injection, which is identified by NDC 50242-051-21. It comes in a 100 mg/10mL (10 mg/mL) vial for intravenous use. The product is marked with an "R" indicating it is available only by prescription.*
Principal Display Panel (500 mg Vial Carton)
This is a medication called Rituxan® (rituximab) which is available in injection form as a 500mg/50mL solution for intravenous use. It is jointly marketed by Biogen and Genentech USA, Inc. The National Drug Code (NDC) assigned to this medication is 50242-053-06.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
